Five articles suggested by Yüksel Ürün
Yüksel Ürün is a Medical Oncology professor at Ankara University School of Medicine in Turkey. His research focuses on genitourinary cancers, covering epidemiology, diagnosis, biomarkers, meta-analysis, and treatment outcomes. His dedication to patient care and research inspires positive change in the medical field.
He suggested following few must-read papers on X:
1.”Redefining first-line options for advanced urothelial carcinoma! Insights on platinum chemotherapy, immunotherapy combos, and patient-tailored strategies.”
Reevaluating the role of platinum-based chemotherapy in the evolving treatment landscape for patients with advanced urothelial carcinoma.
Authors: Tian Zhang, et al.
2.”Patients with mCRPC and BRCA mutations treated with 177Lu-PSMA experienced the poorest overall survival (14.2 months). Sequential PARPi therapy may offer better outcomes.”
Cancer-Control Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer With BRCA Gene or Tumor Suppressor Mutations Undergoing 177-Lutetium Prostate-Specific Membrane Antigen Radioligand Therapy.
Authors: Mike Wenzel, et al.
”
3.”This study shows men with negative mpMRI can safely avoid biopsy, reducing unnecessary procedures without increasing clinically significant prostate cancer (csPCa) risk.”
Oncological Safety of MRI-Informed Biopsy Decision-Making in Men With Suspected Prostate Cancer.
Authors: Charlie A. Hamm, et al.
4.”CLEAR study biomarker analysis: Lenvatinib + Pembrolizumab improved ORR/PFS vs. sunitinib in aRCC, consistent across PD-L1, gene expression, mutations, subtypes.”
Biomarker analyses from the phase 3 randomized CLEAR trial: Lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma.
Authors: R.J. Motzer, et al.
5.”Prostate cancer disparities revealed!
PC incidence varies 13-fold globally; mortality 9.5-fold. Rising rates in Africa, Asia, and Latin America highlight the urgent need for better access to care.”
Recent Patterns and Trends in Global Prostate Cancer Incidence and Mortality: An Update.
Authors: Elizabeth J.Schafer, et al.
More posts featuring Yüksel Ürün.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023